Publication:
Extracellular-vesicle-based cancer panels diagnose glioblastomas with high sensitivity and specificity

dc.contributor.coauthorMut, Melike
dc.contributor.coauthorCakir-Aktas, Canan
dc.contributor.coauthorHanalioglu, Sahin
dc.contributor.coauthorGungor-Topcu, Gamze
dc.contributor.coauthorKiyga, Ezgi
dc.contributor.coauthorIsikay, Ilkay
dc.contributor.coauthorSarac, Aydan
dc.contributor.coauthorSoylemezoglu, Figen
dc.contributor.coauthorStrobel, Thomas
dc.contributor.coauthorAmpudia-Mesias, Elisabet
dc.contributor.coauthorCameron, Charles
dc.contributor.coauthorAslan, Tulay
dc.contributor.coauthorTekirdas, Eray
dc.contributor.coauthorHayran, Mutlu
dc.contributor.coauthorOguz, Kader Karli
dc.contributor.coauthorHenzler, Christine
dc.contributor.coauthorSaydam, Nurten
dc.contributor.coauthorSaydam, Okay
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAdıgüzel, Zelal
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:27:42Z
dc.date.issued2023
dc.description.abstractSimple Summary In this study, we used the RNA sequencing of serum EVs isolated from a large cohort of IDH-wt glioblastoma patients and cancer-free healthy controls to uncover new biological tumor markers with prognostic and diagnostic utility. To our knowledge, this is the first study showing that serum-EV-based biomarker panels can be used to predict/diagnose tumor tissue status in terms of IDH1 mutation, MGMT promoter methylation, TERT promoter mutation, and p53 mutation with a high sensitivity and specificity for glioblastoma. These cancer biomarkers are next-generation precision oncology tools that can be used to (i) predict cancer risk at early stages of the disease, which might offer patients more options and a better chance at overcoming these deadly tumors through surgery or other treatment approaches, and (ii) improve patient stratification and treatment regimes. Glioblastoma is one of the most devastating neoplasms of the central nervous system. This study focused on the development of serum extracellular vesicle (EV)-based glioblastoma tumor marker panels that can be used in a clinic to diagnose glioblastomas and to monitor tumor burden, progression, and regression in response to treatment. RNA sequencing studies were performed using RNA isolated from serum EVs from both patients (n = 85) and control donors (n = 31). RNA sequencing results for preoperative glioblastoma EVs compared to control EVs revealed 569 differentially expressed genes (DEGs, 2XFC, FDR < 0.05). By using these DEGs, we developed serum-EV-based biomarker panels for the following glioblastomas: wild-type IDH1 (96% sensitivity/80% specificity), MGMT promoter methylation (91% sensitivity/73% specificity), p53 gene mutation (100% sensitivity/89% specificity), and TERT promoter mutation (89% sensitivity/100% specificity). This is the first study showing that serum-EV-based biomarker panels can be used to diagnose glioblastomas with a high sensitivity and specificity.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue15
dc.description.openaccessgold, Green Published
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis study was supported, in part, by UMN, Medical School, Start-up, 9404, (O.S.).
dc.description.volume15
dc.identifier.doi10.3390/cancers15153782
dc.identifier.eissn2072-6694
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85167811745
dc.identifier.urihttps://doi.org/10.3390/cancers15153782
dc.identifier.urihttps://hdl.handle.net/20.500.14288/25582
dc.identifier.wos1046099300001
dc.keywordsGlioblastoma
dc.keywordsExtracellular vesicles
dc.keywordsBiomarkers
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofCancers
dc.subjectOncology
dc.titleExtracellular-vesicle-based cancer panels diagnose glioblastomas with high sensitivity and specificity
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAdıgüzel, Zelal
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscoveryd437580f-9309-4ecb-864a-4af58309d287

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR05256.pdf
Size:
2.59 MB
Format:
Adobe Portable Document Format